Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009;60:207-19
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21:v93-7
   PubMed Web of Science ®Google Scholar
• Erbitux: EPAR - Product information - Summary of product characteristics (SmPC). European Medicines Agency (EMA), 2012. http://www.emea.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500029119&mid=WC0b01ac058009a3dc. Accessed December 2012
   Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535-46
   PubMed Web of Science ®Google Scholar
• Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30:1755-62
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-19
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
   PubMed Web of Science ®Google Scholar
• Vectibix: EPAR - Product information - Summary of product characteristics (SmPC). European Medicines Agency (EMA), 2012. http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000741/human_med_001128.jsp&mid=WC0b01ac058001d124. Accessed December 2012
   Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Arnold D, Andre T, Bennouna J, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). 48th Annual ASCO Meeting 2012. Journal of Clinical Oncology 2012;30:suppl:abstr CRA3503). http://www.asco.org. Accessed June 1, 2012
   Google Scholar
• Zaltrap (aflibercept) - Summary of opinion (initial authorisation). European Medicines Agency (EMA), 2012. http://www.emea.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002532/WC500134834.pdf. Accessed February 18, 2013
   Google Scholar
• Zaltrap - Highlights of prescribing information. U S Food and Drug Administration (FDA), 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdf. Accessed February 8, 2013
   Google Scholar
• Van CE, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19
   PubMed Web of Science ®Google Scholar
• Avastin: EPAR - Product information - Summary of product charcteristics (SmPC). European Medicines Agency (EMA), 2012. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf. Accessed December 2012
   Google Scholar
• Arnold D. Electronic and teleconference communication. Freiburg, Germany: Clinic for Medical Oncology, Tumor Biology Center, 2012
   Google Scholar
• Bennouna J. Electronic and teleconference communication. Nantes, France: Institut de Cancérologie de l'Ouest, 2012
   Google Scholar
• Kubicka S. Electronic and teleconference communication. Reutlingen, Germany: German Cancer Center, 2012
   Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, O'Dwyer PJ, et al. Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's Study E3200. J Clin Oncol 2006;ASCO Annual Meeting Proceedings Part I 2006;24:3538
   Google Scholar
• Pfeiffer P, Nielsen D, Yilmaz M, et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007;46:697-701
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008;19:1141-5
   PubMed Web of Science ®Google Scholar
• Siena S, Cassidy J, Tabernero J, et al. Randomized phase 3 study of Panitumumab with FOLFOX4 compared with FOLFOX4 alone as fist-line treatment in patients with metastatic colorectal cancer: the PRIME Trial. ASCO Annual Meeting 2010.
   Google Scholar
• Zhao Z, Pelletier E, Barber B, et al. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Curr Med Res Opin 2012;28:221-9
   PubMed Web of Science ®Google Scholar
• Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7-12
   PubMed Web of Science ®Google Scholar
• Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005;24:67-78
   PubMed Web of Science ®Google Scholar
• Schwander B, Ravera S, Giuliani G, et al. Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy. Clinicoecon Outcomes Res 2012;4:237-43
   PubMedGoogle Scholar
• Escudier B, Goupil MG, Massard C, et al. Sequential therapy in renal cell carcinoma. Cancer 2009;115:2321-6
   PubMed Web of Science ®Google Scholar
• Giusti RM, Shastri K, Pilaro AM, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008;14:1296-302
   PubMed Web of Science ®Google Scholar
• Zafar SY, Currow D, Abernethy AP. Defining best supportive care. J Clin Oncol 2008;26:5139-40
   Google Scholar
• Starling N, Tilden D, White J, et al. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007;96:206-12
   PubMed Web of Science ®Google Scholar